Purpose

A single arm, pilot study among individuals with rosacea and at least moderate flushing or rednesss will be enrolled in a 4-week trial of taVNS. The particicpants will be followed for an additional 4-weeks following the intervention period to evaluate the durability of the results

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adults aged 18 years of age and older - Dermatologist confirmed diagnosis of rosacea - Clinician's Erythema Assessment of at least 3 (moderate to severe disease) - Willingness to adhere to current rosacea regimen without additions or laser treatments (e.g. PDL) during the study period.

Exclusion Criteria

  • Changes to rosacea regimen (prescription topical or oral medications) within 4 weeks of randomization. - Facial hair, tattoos, or other characteristics that would interfere with erythema assessments - History of symptomatic cardiac arrythmias (e.g. heart block, sick sinus syndrome, bradyarrhythmia) - Presence of a pacemaker, implanted defibrillator, or neurostimulator - Seizure disorder or epilepsy - Trigeminal Neuralgia within the past year - Severe coronary disease or recent myocardial infarction within the past 5 years - Severe autonomic dysfunction (e.g., frequent syncope, hospitalization) - History of recurrent syncope or unexplained fainting - Use of brimonidine or oxymetazoline within the past 4 weeks - Use of beta-blockers, anticholinergics, or vagal-modulating drugs within the past 4 weeks - Severe phymatous rosacea - Ear deformity, piercings, or other condition that prevents the use of the taVNS device - Known hypersensitivity to electrode materials - Patients who are pregnant.

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Rosacea
  • Device: Transaricular vagus nerve stimulation (taVNS)
    This project consists of a 4-week trial of transaricular vagus nerve stimulation (taVNS) for rosacea. Participation is expected to last for a total duration of 8 weeks (4 week active intervention period)

Recruiting Locations

Brigham and Women's Hospital
Boston, Massachusetts 02461
Contact:
John Barbieri, MD, MBA
617-264-5926
jbarbieri@bwh.harvard.edu

More Details

Status
Recruiting
Sponsor
Brigham and Women's Hospital

Study Contact

Liset Chacin
617-264-5926
lchacin@bwh.harvard.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.